Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
974 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03565445 | A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 190 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Nov 1, 2024 | clinicaltrials |
| NCT03215511 | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | completed | Phase 1 | 81 | BayerINDUSTRY | 10 | Oct 30, 2024 |
| clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | completed | Phase 1 | 109 | Epizyme, Inc.INDUSTRY | 9 | Oct 3, 2024 | clinicaltrials |
| NCT03546426 | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies(MESOVAX) | active not recruiting | Phase 1 | 18 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT02994953 | A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)(COMBO) | terminated | Phase 1 | 52 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 20, 2024 | clinicaltrials |
| NCT04182516 | Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 52 | Nerviano Medical SciencesINDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT02448589 | An Investigation of TAS-119 Monotherapy | terminated | Phase 1 | 74 | Taiho Oncology, Inc.INDUSTRY | 5 | Sep 4, 2024 | clinicaltrials |
| NCT02454062 | A Trial of TAS-114 in Combination With S-1 | completed | Phase 1 | 120 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 4, 2024 | clinicaltrials |
| NCT02965885 | A Study of TAS-116 in Patients With Solid Tumors | completed | Phase 1 | 31 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 4, 2024 | clinicaltrials |
| NCT03284723 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | terminated | Phase 1 | 95 | PfizerINDUSTRY | 6 | Sep 3, 2024 | clinicaltrials |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 47 | CelgeneINDUSTRY | 5 | Aug 30, 2024 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 53 | Hoffmann-La RocheINDUSTRY | 6 | Aug 23, 2024 | clinicaltrials |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | terminated | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 6 | Aug 15, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | terminated | Phase 1 | 71 | Menarini GroupINDUSTRY | 5 | Aug 12, 2024 | clinicaltrials |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 184 | CelgeneINDUSTRY | 7 | Jul 26, 2024 | clinicaltrials |
| NCT01283945 | Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 134 | Institut de Recherches Internationales ServierOTHER | 3 | Jul 25, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02848443 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | completed | Phase 1 | 78 | Institut de Recherches Internationales ServierOTHER | 7 | Jul 25, 2024 | clinicaltrials |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment | terminated | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 6 | Jul 24, 2024 | clinicaltrials |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 97 | IGM Biosciences, Inc.INDUSTRY | 7 | Jul 24, 2024 | clinicaltrials |
| NCT02549937 | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 130 | HutchmedINDUSTRY | 2 | Jul 10, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT03301896 | Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 20, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT04074330 | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 38 | TakedaINDUSTRY | 9 | Jun 14, 2024 | clinicaltrials |
| NCT04580121 | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | completed | Phase 1 | 59 | Hoffmann-La RocheINDUSTRY | 10 | Jun 3, 2024 | clinicaltrials |
| NCT01492088 | Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 36 | Millennium Pharmaceuticals, Inc.INDUSTRY | 8 | May 30, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 600 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | May 3, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT00953758 | A Study Of PF-04449913 In Select Hematologic Malignancies | completed | Phase 1 | 47 | PfizerINDUSTRY | 2 | Apr 25, 2024 | clinicaltrials |
| NCT02085148 | A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy | completed | Phase 1 | 62 | BayerINDUSTRY | 4 | Apr 22, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT04524455 | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | completed | Phase 1 | 17 | AmgenINDUSTRY | 9 | Apr 8, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials